TRACY D. WILKINS;JAMES HUNTER BOONE;DAVID M. LYERLY;ROBERT J. CARMAN
发明人:
JAMES HUNTER BOONE,DAVID M. LYERLY,TRACY D. WILKINS,ROBERT J. CARMAN
申请号：
US13457049
公开号：
US20120276059A1
申请日:
2012.04.26
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
